Prenatal and newborn screening for hemoglobinopathies

International Journal of Laboratory Hematology

Volumn 35, Issue 3, 2013, Pages 297-305

  Hoppe, C C ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Hemoglobinopathies; Methods; Newborn screening; Prenatal testing; Review

Indexed keywords

ALPHA THALASSEMIA; BETA THALASSEMIA; BLOOD CELL COUNT; CAPILLARY ELECTROPHORESIS; DNA SEQUENCE; ELECTROPHORESIS; ERYTHROCYTE TRANSFUSION; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC ANALYSIS; HEMOGLOBINOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MUTATIONAL ANALYSIS; NEWBORN SCREENING; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; REVIEW; SICKLE CELL ANEMIA;

FEMALE; FETAL DISEASES; GENETIC TESTING; HEMOGLOBINOPATHIES; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PREGNANCY; PRENATAL DIAGNOSIS; PREVENTIVE HEALTH SERVICES;

EID: 84876491483     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12076     Document Type: Review

References (32)

1. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003;101:791-800.
2. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480-7.
3. Vichinsky EP, MacKlin EA, Waye JS, Lorey F, Olivieri NF. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005;116:e818-25.
4. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38(Suppl.4):S512-21.
5. Lorey F, Cunningham G, Vichinsky EP, Lubin BH, Witkowska HE, Matsunaga A, Azimi M, Sherwin J, Eastman J, Farina F, Waye JS, Chui DH. Universal newborn screening for Hb H disease in California. Genet Test 2001;5:93-100.
6. Michlitsch J, Azimi M, Hoppe C, Walters MC, Lubin B, Lorey F, Vichinsky E. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009;52:486-90.
7. Wang Y, Kennedy J, Caggana M, Zimmerman R, Thomas S, Berninger J, Harris K, Green NS, Oyeku S, Hulihan M, Grant AM, Grosse SD. Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. Genet Med 2012, doi: 10.1038/gim.2012.128.
8. Kidd JL, Azimi M, Lubin B, Vichinsky E, Hoppe C. Application of an expanded multiplex genotyping assay for the simultaneous detection of Hemoglobin Constant Spring and common deletional alpha-thalassemia mutations. Int J Lab Hematol 2010;32:373-80.
9. Fucharoen S, Winichagoon P. Thalassemia in SouthEast Asia: problems and strategy for prevention and control. Southeast Asian J Trop Med Public Health 1992;23:647-55.
10. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2012;364:710-8.
11. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 2010;18:1077-83.
12. Langlois S, Ford JC, Chitayat D, Desilets VA, Farrell SA, Geraghty M, Nelson T, Nikkel SM, Shugar A, Skidmore D, Allen VM, Audibert F, Blight C, Gagnon A, Johnson JA, Wilson RD, Wyatt P. Carrier screening for thalassemia and hemoglobinopathies in Canada. J Obstet Gynaecol Can 2008;30:950-71.
13. Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002;29:305-28, vi-vii.
14. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000;4:i-v, 1-99.
15. Greengross P, Hickman M, Gill M, Dugan B, Davies SC. Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen 1999;6:3-10.
16. Rappaport VJ, Velazquez M, Williams K. Hemoglobinopathies in pregnancy. Obstet Gynecol Clin North Am 2004;31:287-317, vi.
17. ACOG (American College of Obstetricians and Gynecologists) committee opinion. Genetic screening for hemoglobinopathies, number 238, July 2000 (replaces number 168, February 1996) Committee on Genetics. Int J Gynaecol Obstet 2001;74:309-10.
18. Vichinsky EP. Alpha thalassemia major-new mutations, intrauterine management, and outcomes. Hematology Am Soc Hematol Educ Program 2009;35-41.
19. Old JM. Prenatal diagnosis of the hemoglobinopathies. In: Genetic Disorders and the Fetus. Milunsky A. (ed). Baltimore: Johns Hopkins University Press; 1998: 581-611.
20. Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 1996;14:264-8.
21. Lo YM. Recent advances in fetal nucleic acids in maternal plasma. J Histochem Cytochem 2005;53:293-6.
22. Phylipsen M, Yamsri S, Treffers EE, Jansen DT, Kanhai WA, Boon EM, Giordano PC, Fucharoen S, Bakker E, Harteveld CL. Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis. Prenat Diagn 2012;32:578-87.
23. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-9.
24. Benson JM, Therrell BL, Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol 2010;34:134-44.
25. Eastman JW, Wong R, Liao CL, Morales DR. Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. Clin Chem 1996;42:704-10.
26. Joutovsky A, Hadzi-Nesic J, Nardi MA. HPLC retention time as a diagnostic tool for hemoglobin variants and hemoglobinopathies: a study of 60000 samples in a clinical diagnostic laboratory. Clin Chem 2004;50:1736-47.
27. Harteveld CL, Voskamp A, Phylipsen M, Akkermans N, den Dunnen JT, White SJ, Giordano PC. Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet 2005;42:922-31.
28. Phylipsen M, Chaibunruang A, Vogelaar IP, Balak JR, Schaap RA, Ariyurek Y, Fucharoen S, den Dunnen JT, Giordano PC, Bakker E, Harteveld CL. Fine-tiling array CGH to improve diagnostics for alpha- and beta-thalassemia rearrangements. Hum Mutat 2012;33:272-80.
29. Feuchtbaum L, Dowray S, Lorey F. The context and approach for the California newborn screening short- and long-term follow-up data system: preliminary findings. Genet Med 2010;12(Suppl.12):S242-50.
30. Sickle cell disease: comprehensive screening and management in newborns and infants. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1993;1-13.
31. Kavanagh PL, Wang CJ, Therrell BL, Sprinz PG, Bauchner H. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet 2008;148C:15-22.
32. From the Centers for Disease Control Prevention. Update: newborn screening for sickle cell disease-California, Illinois, and New York, 1998. JAMA 2000;284:1373-4.